MicroPort CardioFlow Medtech Corp. operates as a holding company with interest in developing medical devices. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-02-04. The Company’s main business is engaged in the research and development and commercialization of transcatheter and surgical solutions for structural heart diseases. The Company’s pipelines include transcatheter aortic heart valve implantation (TAVI) series products, AnchorMan left atrial appendage closure (LAAC) product, transcatheter mitral valve (TMV) products, transcatheter tricuspid valve (TTV) products and procedural accessories. The firm conducts its business in the domestic and overseas markets.
Follow-Up Questions
MROPF の株価パフォーマンスは？
MROPF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Microport Cardioflow Medtech Corp の主な事業テーマや業界は？
Microport Cardioflow Medtech Corp は Health Care 業界、セクターは Health Care に属しています。
